1.
Sobell JM, Elewski B, Banerjee S, Balagula E, Scharnitz T, Berger V, Hoyt K, Yamauchi P, Bettencourt M, Cameron MC, Lebwohl M. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI). J of Skin [Internet]. 2023Nov.13 [cited 2024Jul.15];7(6):s238. Available from: https://www.jofskin.org/index.php/skin/article/view/2355